Most cited papers in Multiple Sclerosis Research Studies
What are the most cited papers in Multiple Sclerosis Research Studies?
The most cited paper in Multiple Sclerosis Research Studies is "Rating neurologic impairment in multiple sclerosis" (John F. Kurtzke, 1983), with 15,106 citations. Next come "Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria" (9,914) and "Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria" (8,265).
Showing 50 of 97 papers. Every paper with more than 1,141 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Rating neurologic impairment in multiple sclerosis John F. Kurtzke · Neurology | Nov 1983 | 15,106 |
| 2 | Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria Chris H. Polman, Stephen C. Reingold, Brenda Banwell et al. · Annals of Neurology | 11 Jan 2011 | 9,914 |
| 3 | Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria Alan J. Thompson et al. · The Lancet Neurology | 21 Dec 2017 | 8,265 |
| 4 | New diagnostic criteria for multiple sclerosis: Guidelines for research protocols Charles M. Poser, Donald W. Paty, Labe C. Scheinberg et al. · Annals of Neurology | Mar 1983 | 7,423 |
| 5 | Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis W. I. McDonald, Alistair Compston, Gilles Edan et al. · Annals of Neurology | 26 Jun 2001 | 6,993 |
| 6 | The Fatigue Severity Scale Lauren Krupp · Archives of Neurology | Oct 1989 | 6,141 |
| 7 | Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Valery L. Feigin et al. · The Lancet Neurology | 14 Mar 2019 | 5,824 |
| 8 | Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” Chris H. Polman, Stephen C. Reingold, Gilles Edan et al. · Annals of Neurology | 10 Nov 2005 | 5,023 |
| 9 | International consensus diagnostic criteria for neuromyelitis optica spectrum disorders Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett et al. · Neurology | 19 Jun 2015 | 4,664 |
| 10 | Multiple sclerosis Alastair Compston, Alasdair J. Coles · The Lancet | Oct 2008 | 4,397 |
| 11 | Axonal Transection in the Lesions of Multiple Sclerosis Bruce D. Trapp, John W. Peterson, Richard M. Ransohoff et al. · New England Journal of Medicine | 29 Jan 1998 | 4,062 |
| 12 | Defining the clinical course of multiple sclerosis FRED D. LUBLIN, Stephen C. Reingold · Neurology | Apr 1996 | 3,705 |
| 13 | A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis Chris H. Polman, Paul W O'Connor, Eva Havrdová et al. · New England Journal of Medicine | Mar 2006 | 3,396 |
| 14 | Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination Claudia Francesca Lucchinetti, Wolfgang Br�ck, Joseph E. Parisi et al. · Annals of Neurology | Jun 2000 | 3,370 |
| 15 | A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis Vanda A. Lennon, Dean M. Wingerchuk, Thomas J. Kryzer et al. · The Lancet | Dec 2004 | 3,258 |
| 16 | Multiple Sclerosis John H. Noseworthy, Claudia Francesca Lucchinetti, Moses Rodriguez et al. · New England Journal of Medicine | 28 Sep 2000 | 2,909 |
| 17 | Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis Stephen J. Sawcer et al. · Nature | Aug 2011 | 2,772 |
| 18 | Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition Clare Walton, Rachel King, Lindsay Rechtman et al. · Multiple Sclerosis Journal | 11 Nov 2020 | 2,668 |
| 19 | A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis Ludwig Kappos, Ernst‐Wilhelm Radue, Paul O’Connor et al. · New England Journal of Medicine | 20 Jan 2010 | 2,658 |
| 20 | 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus Martin Aringer et al. · Arthritis & Rheumatology | 6 Aug 2019 | 2,644 |
| 21 | Revised diagnostic criteria for neuromyelitis optica Dean M. Wingerchuk, Vanda A. Lennon, Sean Joseph Pittock et al. · Neurology | May 2006 | 2,585 |
| 22 | Multiple Sclerosis Daniel S. Reich, Claudia Francesca Lucchinetti, Peter A. Calabresi · New England Journal of Medicine | 10 Jan 2018 | 2,532 |
| 23 | Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis Lawrence D. Jacobs et al. · Annals of Neurology | Mar 1996 | 2,458 |
| 24 | B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis Stephen L. Hauser, Emmanuelle L. Waubant, Douglas Lorne Arnold et al. · New England Journal of Medicine | 13 Feb 2008 | 2,441 |
| 25 | IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel Vanda A. Lennon, Thomas J. Kryzer, Sean Joseph Pittock et al. · The Journal of Experimental Medicine | 8 Aug 2005 | 2,299 |
| 26 | Immunopathology of multiple sclerosis Calliope Athena Dendrou, Lars H. Fugger, Manuel Alexander Friese · Nature reviews. Immunology | 7 Aug 2015 | 2,260 |
| 27 | Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis Jeffrey A. Cohen, Frederik Barkhof, Gıancarlo Comı et al. · New England Journal of Medicine | 20 Jan 2010 | 2,217 |
| 28 | The spectrum of neuromyelitis optica Dean M. Wingerchuk, Vanda A. Lennon, Claudia Francesca Lucchinetti et al. · The Lancet Neurology | 14 Aug 2007 | 2,195 |
| 29 | Multiple sclerosis – a review Ruth Dobson, Gavin Giovannoni · European Journal of Neurology | 10 Oct 2018 | 2,167 |
| 30 | IMMUNOLOGY OF MULTIPLE SCLEROSIS Mireia Sospedra, Roland Martinꝉ · Annual Review of Immunology | 19 Jan 2005 | 2,156 |
| 31 | Cognitive dysfunction in multiple sclerosis. Stephen M. Rao, Gary J. Leo, Linda Bernardin et al. · Neurology | May 1991 | 2,125 |
| 32 | Cognitive impairment in multiple sclerosis Nancy D. Chiaravalloti, John DeLuca · The Lancet Neurology | 12 Nov 2008 | 2,107 |
| 33 | Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial Sandra Navarra, Renato Guzmán, A Gallacher et al. · The Lancet | Feb 2011 | 2,098 |
| 34 | Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis Kjetil Bjørnevik, Marianna Cortese, Brian C. Healy et al. · Science | 14 Jan 2022 | 2,077 |
| 35 | Interpreting scores on the Kessler Psychological Distress Scale (K10) Gavin Andrews, Tim N Slade · Australian and New Zealand Journal of Public Health | Dec 2001 | 2,067 |
| 36 | Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis Stephen L. Hauser et al. · New England Journal of Medicine | 21 Dec 2016 | 2,042 |
| 37 | Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis Donald W. Paty, D.K.B. Li, the UBC MS/MRI Study Group et al. · Neurology | Apr 1993 | 1,975 |
| 38 | Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis Xavier Montalbán et al. · New England Journal of Medicine | 21 Dec 2016 | 1,913 |
| 39 | Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis Kassandra L. Munger, Lynn I. Levin, Bruce W. Hollis et al. · JAMA | 19 Dec 2006 | 1,907 |
| 40 | Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis K. P. Johnson, Benjamin Brooks, J. A. Cohen et al. · Neurology | Jul 1995 | 1,906 |
| 41 | Cortical demyelination and diffuse white matter injury in multiple sclerosis Alexandra Kutzelnigg, Claudia Francesca Lucchinetti, Christine Stadelmann et al. · Brain | 17 Oct 2005 | 1,857 |
| 42 | The clinical course of neuromyelitis optica (Devic’s syndrome) Dean M. Wingerchuk, William F. Hogancamp, Peter C. O’Brien et al. · Neurology | Sep 1999 | 1,830 |
| 43 | Multiple sclerosis Alan J. Thompson, Sergio E. Baranzini, Jeroen J.G. Geurts et al. · The Lancet | 23 Mar 2018 | 1,825 |
| 44 | Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia Sheng‐Kwei Song, Shu‐Wei Sun, Won‐Kyu Ju et al. · NeuroImage | 15 Oct 2003 | 1,777 |
| 45 | Multiple Sclerosis — The Plaque and Its Pathogenesis Elliot M. Frohman, Michael K. Racke, Cedric S. Raine · New England Journal of Medicine | Mar 2006 | 1,768 |
| 46 | Autonomic Dysregulation, Cognitive Impairment, and Symptoms of Psychosis as an Unusual Presentation in an Anti-Aquaporin 4-Positive Patient. Annabel M. Ruiter, Jan F Meilof, Rosemarijn R. J. Somanje-Bolweg et al. · PubMed | 6 Feb 2017 | 1,761 |
| 47 | Multiple Sclerosis: An Immune or Neurodegenerative Disorder? Bruce D. Trapp, Klaus‐Armin Nave · Annual Review of Neuroscience | 17 Jun 2008 | 1,742 |
| 48 | Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis Ralf Gold, Ludwig Kappos, Douglas Lorne Arnold et al. · New England Journal of Medicine | 19 Sep 2012 | 1,735 |
| 49 | Demyelination increases radial diffusivity in corpus callosum of mouse brain Sheng-Kwei Song, Jun Yoshino, Tuan Q. Le et al. · NeuroImage | 8 Mar 2005 | 1,696 |
| 50 | A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus Richard Alan Furie, Michelle Petri, Omid Zamani et al. · Arthritis & Rheumatism | Sep 2011 | 1,693 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.